Alkermes Rides Into 2014 On Abilify’s Coattails
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on its experience in long-acting injectables, Alkermes is preparing to file an NDA for its long-acting version of Otsuka/Bristol-Myers Squibb’s antipsychotic Abilify in 2014.
You may also be interested in...
Otsuka Tries To Halt Alkermes Ride On Abilify’s Coattails
FDA should not review or approve Alkermes’ NDA for aripiprazole lauroxil because it is based on only one adequate and well-controlled clinical trial, Otsuka argues.
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.